SymbioPharm GmbH

Name

SymbioPharm GmbH

Legal name

SymbioPharm GmbH

Website

https://symbiopharm.de

Company type

Private

Founded year

1954

Operating status

Operating

Ownership category

akta.pro rank

Product category

Probiotic Pharmaceuticals and Supplements

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

akta.pro secondary industries

Probiotic, Prebiotic & Gut-Health Foods Manufacturing (Fermented Functional Foods, Synbiotics) (AFAKAJAH), Probiotics (Human & Animal Strains, Spore-Formers, Synbiotic Bases) (AFAJAJAE), Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)

Keywords

• Probiotic medications
• Probiotic supplements
• Microbiome therapy
• Lactic acid bacteria
• Pharmaceutical probiotics

Headquarters

HQ city

Herborn

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. B2C Probiotic Product Sales: Direct sales of probiotic medications (Symbioflor®), dietary supplements (SymbioLact®, SymbioLife®), and health products to consumers through pharmacies and online pharmacy platforms.
2. Pet Health Products: Sales of probiotic pet supplements (SYMBIO pet® DOG) through pharmacies and pet stores for canine gut health.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

SymbioPharm GmbH develops, manufactures, and distributes knowledge-based probiotic pharmaceutical and dietary supplement products built on seven decades of microbiome research. Its portfolio includes registered probiotic medications (Symbioflor® 1 and 2) for respiratory infections and irritable bowel syndrome, precision-bacteria products (SymbioLife®), lactic-acid-bacteria dietary supplements (SymbioLact®), and adjacent lines for intimate, skin, immune, metabolic, oral, and pet health, sold primarily through pharmacies in Germany and Austria and via 14 international distribution partners.

Differentiator

Problem solved

Functional benefit

Brands

• Symbioflor: Probiotic medicinal products for treating respiratory tract infections and irritable bowel syndrome
• SymbioLife
• SymbioLact
• Symbiofem
• SymbioDermal
• Symbio Intest
• SYMBIO pet
• PolyZink
• Parodolium
• Pro-Symbioflor

Products and services

• Symbioflor® 1 - Probiotic Medication for Respiratory Diseases
• Symbioflor® 2 - Probiotic Medication for Irritable Bowel Syndrome
• SymbioLife® - Precision Bacteria Product Line
• SymbioLact® - Lactic Acid Bacteria Product Line
• Pro-Symbioflor® Immun - Immune Support Product
• Symbio Intest® - Prebiotic Fibers
• Symbio Dermal® - Microbiotic Skin Care
• Symbiofem® - Women's Intimate Health Line
• PolyZink® - Immune Support with Zinc
• Parodolium® - Oral Rinse Concentrate
• SYMBIO pet® DOG - Probiotic Supplement for Dogs

Quantifiable outcome

• In a clinical study with 298 patients, 18.2% of Symbioflor® 2 treated patients achieved complete symptom freedom after 8 weeks.

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• TargEDyscoreStrategic or Co-development PartnerSymbioPharm and TargEDys established an exclusive partnership for the distribution and development of Satylia®, the first precision probiotic. This partnership focuses on precision bacteria for weight management and metabolic health, combining TargEDys's specialized bacterial strains with SymbioPharm's distribution network and expertise in probiotic products.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioGaia: Swedish probiotic specialist selling clinically-documented Lactobacillus reuteri strains through pharmacy and consumer health channels globally. Direct competitor in the evidence-based probiotic segment with similar focus on strain-specific health claims and pharmacy distribution in Europe.
• Yakult Honsha: Japanese probiotic beverage and supplement company with the flagship Yakult brand built on Lactobacillus casei strain Shirota. Comparable in being a probiotic-specialist with deep scientific heritage, though Yakult is much larger and beverage-focused.
• Probi AB: Swedish probiotic ingredient and finished product company with documented strains sold through B2B partners and consumer brands. Direct comparable in scale and business model, supplying both probiotic ingredients and finished formulations.
• Winclove Probiotics: Dutch probiotic specialist developing multi-strain formulations for specific indications, sold through pharmacy and practitioner channels in Europe. Closely comparable in business model, European focus, and indication-specific probiotic positioning.
• Lallemand Health Solutions: Canadian probiotic manufacturer producing strain-specific formulations for gut, immune, and mental health sold globally through supplement brands. Comparable in evidence-based probiotic development and B2B supply model.
• Protexin (ADM Protexin): UK-based probiotic manufacturer (now part of ADM) with Bio-Kult and other multi-strain brands sold globally. Comparable in evidence-based probiotic development across human and pet applications including pet supplements similar to SYMBIO pet.

Broad incumbents

• Chr. Hansen (Novonesis): Global leader in microbial and probiotic cultures across food, supplements, and pharma. Now part of Novonesis post-merger with Novozymes. Much larger scale; supplies probiotic strains to many branded competitors including SymbioPharm-type players.
• Danone (Nutricia): Global CPG leader with Activia, Actimel, and gut-health portfolio including Nutricia medical nutrition. Far larger scale and broader distribution; SymbioPharm competes in adjacent probiotic spaces particularly in DACH retail channels.
• Bayer Consumer Health: Large pharmaceutical and consumer health company selling probiotics and gut-health products through German pharmacy channels (e.g., Iberogast, Kijimea). Direct channel competitor with vastly greater marketing and distribution scale.

Emerging players

• TargEDys: French biotech developing precision probiotic Hafnia alvei-based products for metabolic health. Currently SymbioPharm's partner but a peer in precision probiotic development; if their partnership unwinds TargEDys would compete directly.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/SymbioPharm
• LinkedInlinkedin.com/company/symbiopharm-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SymbioPharm GmbH